Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10555-014-9538-9 http://scihub22266oqcxt.onion/10.1007/s10555-014-9538-9 C4369424!4369424!25544368     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Metastasis+Rev 2015 ; 34 (1): 19-40 Nephropedia Template TP {{tp|p=25544368|t=2015. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches |pdf=|usr=}}{{25544368}} gab.com Text Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches JO: Cancer Metastasis Rev http://www.kidney.de/pget.php?&tw=1&pmid=25544368 #FOAvip Resistance to chemotherapy is among the most important issues in the management of ovarian cancer. Unlike cancer cells, which are heterogeneous as a result of remarkable genetic instability, stromal cells are considered relatively homogeneous. Thus, targeting the tumor microenvironment is an attractive approach for cancer therapy. Arguably, anti-vascular endothelial growth factor (anti-VEGF) therapies hold great promise, but their efficacy has been modest, likely owing to redundant and complementary angiogenic pathways. Components of platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and other pathways may compensate for VEGF blockade and allow angiogenesis to occur despite anti-VEGF treatment. In addition, hypoxia induced by antiangiogenesis therapy modifies signaling pathways in tumor and stromal cells, which induces resistance to therapy. Because of tumor cell heterogeneity and angiogenic pathway redundancy, combining cytotoxic and targeted therapies or combining therapies targeting different pathways can potentially overcome resistance. Although targeted therapy is showing promise, much more work is needed to maximize its impact, including the discovery of new targets and identification of individuals most likely to benefit from such therapies. Twit Text FOAVip Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches ????Cancer Metastasis Rev http://www.kidney.de/pget.php?&tw=1&pmid=25544368 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25544368 #FOAvip English Wikipedia <ref>{{Cite pmid|25544368}}</ref> Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches #MMPMID25544368 Choi HJ; Pena GNA; Pradeep S; Cho MS; Coleman RL; Sood AK Cancer Metastasis Rev 2015[Mar]; 34 (1): 19-40 PMID25544368show ga Resistance to chemotherapy is among the most important issues in the management of ovarian cancer. Unlike cancer cells, which are heterogeneous as a result of remarkable genetic instability, stromal cells are considered relatively homogeneous. Thus, targeting the tumor microenvironment is an attractive approach for cancer therapy. Arguably, anti-vascular endothelial growth factor (anti-VEGF) therapies hold great promise, but their efficacy has been modest, likely owing to redundant and complementary angiogenic pathways. Components of platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and other pathways may compensate for VEGF blockade and allow angiogenesis to occur despite anti-VEGF treatment. In addition, hypoxia induced by antiangiogenesis therapy modifies signaling pathways in tumor and stromal cells, which induces resistance to therapy. Because of tumor cell heterogeneity and angiogenic pathway redundancy, combining cytotoxic and targeted therapies or combining therapies targeting different pathways can potentially overcome resistance. Although targeted therapy is showing promise, much more work is needed to maximize its impact, including the discovery of new targets and identification of individuals most likely to benefit from such therapies. äAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF app(epmc).pdf DeepDyve Pubget Overpricing